Jag Chhatwal, PhD, is the Director of the Institute for Technology Assessment at Massachusetts General Hospital and an associate professor at Harvard Medical School. He is also a faculty member of the Center for Health Decision Science at Harvard T.H. Chan School of Public Health and an affiliate of Harvard Data Science Initiative. He has co-authored over 125 original research articles and editorials in peer-reviewed journals. His work has been cited in leading media outlets, including CNN, Forbes, National Public Radio, New York Times, and Wall Street Journal. His economic modeling research has informed policy decisions made by the White House, the World Health Organization, and the CDC. He is a member of ISPOR AI Working Group. He also serves as an Associate Editor of Value in Health and as the guest editor for special issues on AI in Value in Health.
Turgay Ayer, PhD, holds the Virginia C. and Joseph C. Mello Chair and is the Research Director for Healthcare Analytics and Business Intelligence at the Center for Health & Humanitarian Systems at Georgia Tech. He is also the Chief Technology Officer at Value Analytics Labs. Dr. Ayer holds a courtesy appointment at Emory Medical School where he teaches Big Data Analytics courses and serves as a Senior Scientist at the Centers for Disease Control and Prevention (CDC). Dr. Ayer’s research focuses on HEOR, real-world evidence, data science, machine learning, and healthcare analytics. He has published over 70 peer-reviewed journal papers and over 250 conference abstracts, featuring his work in top-tier business, engineering, medical, and health policy journals. His research has attracted substantial attention from major media outlets, including The Wall Street Journal, The Washington Post, US News, and NPR.
Rachael Fleurence, PhD, is a Senior Advisor to Dr. Francis Collins at the National Institutes of Health. Dr Fleurence is also affiliated with the National Institute of Biomedical Imaging and Bioengineering (NIBIB), where she works on advances in Artificial Intelligence and Machine Learning. Previously, Dr Fleurence served as a senior health policy advisor in the Biden-Harris White House and served as Senior Advisor to the NIH Director at the NIH. Dr. Fleurence served on the White House Pandemic Testing Board policy group, and the White House Pandemic Innovation Task Force in 2021-2022. Dr Fleurence received three NIH Director’s Awards for exceptional dedication and innovation in advancing COVID-19 testing efforts and the HHS Secretary’s Award for Distinguished Service. She was also named a 2023 “National Champion for Global Hepatitis Elimination” along with Dr Francis Collins. Before her role at the White House and NIH, Dr. Fleurence served as the Executive Director of the National Evaluation System for Health Technology (NESTcc) and the Program Director for PCORnet for PCORI. Dr. Fleurence received a BA from Cambridge University (United Kingdom), an MA in business management from ESSEC-Paris (France), and an MSc in health economics and PhD in health sciences, both from the University of York (United Kingdom).
Ipek Ozer Stillman, MBA, MSc, is an experienced bio-pharma leader in areas of Value, Evidence, and Access with two decades of experience in the healthcare and biopharmaceutical industry. Her career journey is fueled by her passion for driving a positive, sustainable impact in healthcare globally. She thrives on developing innovative strategies that include multidisciplinary approaches, leveraging her expertise at the intersection of business strategy, data analytics, digital transformation, and health policy.
Currently, she is the Head of Global Health Economics at Takeda. She has worked at Takeda for about nine years, including a prior role within the Shire R&D organization as part of the Health Economics, Outcomes Research, and Epidemiology group. Before Takeda, Ipek worked for over ten years at Evidera/ PPD, at a large global research consultancy, leading their Modeling and Simulation teams in Boston and San Francisco and collaborating with global biotechnology and pharmaceutical clients. Ipek holds a Master of Business Administration degree from MIT Sloan School of Management and a Master of Science in Mechanical Engineering from Northeastern University.
Dalia Dawoud, PhD, is Associate Director (Research) at the National Institute for Health and Care Excellence (NICE). She has over 20 years experience as health economist and researcher. Her current work is focused on advancing HTA and clinical guideline development methods through research. Dr. Dawoud leads NICE newly established HTA Innovation Laboratory (HTA Lab) as well as NICE’s portfolio of European Commission funded projects, such as IHI IDERHA and SYNTHIA, with cumulative funding of over 5 million Euros. She is widely published in the area of health economics and outcomes research and serves as Associate Editor of ISPOR journal Value in Health and as Director on ISPOR Board of Directors (2023-2026)